cx-516 cx-516 cx-516 is an ampakine and nootropic that acts as an ampa receptor positive allosteric modulator and had been undergoing development by a collaboration between cortex, shire, and servier. it was studied as a potential treatment for alzheimer's disease under the brand name ampalex, and was also being examined as a treatment for adhd. cx-516pharmacokinetic dataelimination half-life45 minutesidentifiers iupac name 6-(piperidin-1-ylcarbonyl)quinoxaline cas number154235-83-3 ypubchem cid148184iuphar/bps4165chemspider130635 yuniiz5qu38b4v9keggc13675 ychemblchembl136800 ycomptox dashboard (epa)dtxsid70165574 echa infocard100.237.047 chemical and physical dataformulac14h15n3omolar mass241.294 g·mol−13d model (jsmol)interactive image smiles o=c(c2cc1nccnc1cc2)n3ccccc3 inchi inchi=1s/c14h15n3o/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10h,1-3,8-9h2 ykey:andggvopijehof-uhfffaoysa-n y (verify) cx-516 was the first ampakine compound developed by cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. however, cx-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and cx-717 are compared to.